Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERAS Erasca	$1.64 +4.5%	$1.48	$1.01 ▼ $3.31	$465.22M	1.07	1.40 million shs	456,780 shs
GOSS Gossamer Bio	$1.96	$1.56	$0.66 ▼ $2.23	$445.67M	1.96	1.94 million shs	1.73 million shs
OKYO OKYO Pharma	$2.65 +0.4%	$2.69	$0.85 ▼ $3.35	$99.67M	-0.09	174,310 shs	709,944 shs
TNXP Tonix Pharmaceuticals	$51.43 -13.7%	$41.16	$6.76 ▼ $130.00	$451.08M	1.7	1.34 million shs	2.79 million shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERAS Erasca	-3.09%	+7.53%	+11.35%	+22.18%	-39.38%
GOSS Gossamer Bio	-0.51%	+12.64%	+35.17%	+88.46%	+137.00%
OKYO OKYO Pharma	-1.12%	-16.46%	-4.00%	+78.38%	+164.03%
TNXP Tonix Pharmaceuticals	-3.23%	+26.98%	+34.80%	+112.79%	+18.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERAS Erasca	2.4332 of 5 stars	3.5	1.0	0.0	2.5	2.5	0.6
GOSS Gossamer Bio	3.9117 of 5 stars	3.5	1.0	4.7	3.1	1.7	0.0
OKYO OKYO Pharma	3.1547 of 5 stars	3.5	5.0	0.0	3.1	1.7	0.0
TNXP Tonix Pharmaceuticals	3.0781 of 5 stars	3.5	2.0	0.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERAS Erasca	3.00	Buy	$4.57	178.75% Upside
GOSS Gossamer Bio	3.00	Buy	$8.50	333.67% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	164.15% Upside
TNXP Tonix Pharmaceuticals	3.00	Buy	$70.00	36.10% Upside

Current Analyst Ratings Breakdown

Latest OKYO, ERAS, TNXP, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$4.00 ➝ $5.00
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
6/3/2025	TNXP Tonix Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERAS Erasca	N/A	N/A	N/A	N/A	$1.31 per share	N/A
GOSS Gossamer Bio	$114.70M	3.89	N/A	N/A	($0.20) per share	-9.80
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A
TNXP Tonix Pharmaceuticals	$10.09M	44.71	N/A	N/A	$19.17 per share	2.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERAS Erasca	-$161.65M	-$0.45	N/A	N/A	N/A	N/A	-31.19%	-26.34%	N/A
GOSS Gossamer Bio	-$56.53M	-$0.62	N/A	N/A	N/A	-344.81%	-1,774.72%	-46.73%	N/A
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	-$130.04M	-$39.47	N/A	N/A	N/A	-828.22%	-57.93%	-51.04%	8/15/2025 (Estimated)

Latest OKYO, ERAS, TNXP, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ERAS Erasca	-$0.12	-$0.12	N/A	-$0.12	N/A	N/A
8/11/2025	Q1 2025	TNXP Tonix Pharmaceuticals	-$3.10	-$3.86	-$0.76	-$3.86	$2.60 million	$2.00 million
8/5/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	-$0.17	+$0.01	-$0.17	$4.12 million	$11.49 million
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERAS Erasca	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A
TNXP Tonix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERAS Erasca	N/A	11.03	12.35
GOSS Gossamer Bio	6.70	4.40	4.40
OKYO OKYO Pharma	N/A	0.40	0.40
TNXP Tonix Pharmaceuticals	N/A	7.53	11.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERAS Erasca	67.78%
GOSS Gossamer Bio	81.23%
OKYO OKYO Pharma	2.97%
TNXP Tonix Pharmaceuticals	82.26%

Insider Ownership

Company	Insider Ownership
ERAS Erasca	14.40%
GOSS Gossamer Bio	6.70%
OKYO OKYO Pharma	40.46%
TNXP Tonix Pharmaceuticals	0.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERAS Erasca	120	283.67 million	242.49 million	Optionable
GOSS Gossamer Bio	180	227.38 million	212.15 million	Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable
TNXP Tonix Pharmaceuticals	50	8.77 million	8.76 million	Not Optionable

OKYO, ERAS, TNXP, and GOSS Headlines

Recent News About These Companies

Tonix Pharmaceuticals Announces FDA Approval of Tonmya, the First New Fibromyalgia Therapy in Over 15 Years

1 hour ago | quiverquant.comQ

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

1 hour ago | reuters.com

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

1 hour ago | globenewswire.com

Tonix Pharma Gears Up For Key FDA Decision Today, Stock Up Over 500% In 5 Months

August 15 at 6:25 AM | rttnews.com

Companies Like Tonix Pharmaceuticals Holding (NASDAQ:TNXP) Are In A Position To Invest In Growth

August 14 at 11:42 PM | finance.yahoo.com

What's Going On With Tonix Pharmaceuticals (TNXP) Stock?

August 14 at 4:14 PM | benzinga.com

Caitong International Asset Management Co. Ltd Takes $405,000 Position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

August 14 at 7:07 AM | marketbeat.com

Tonix Pharma: Eyes On FDA Deadline This Friday, I See A 65% Approval Potential

August 13 at 1:07 PM | seekingalpha.com

Why Tonix Pharmaceuticals (TNXP) Stock Is Climbing This Week

August 13 at 11:17 AM | benzinga.com

Tonix Pharma Scores Best Day Since March On Hopes For First New Fibromyalgia Drug Approval in 16 Years; Retail’s Optimistic

August 13 at 2:35 AM | msn.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Posts Quarterly Earnings Results, Beats Estimates By $2.85 EPS

August 12 at 9:25 PM | marketbeat.com

Tonix Pharmaceuticals Reports Q2 2025 EPS Loss of $3. ...

August 12 at 8:40 PM | gurufocus.com

Tonix Pharmaceuticals (TNXP) Stock Surges On Q2 Earnings Beat And Upcoming FDA Catalyst

August 12 at 12:43 PM | benzinga.com

Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

August 12 at 6:32 AM | finanznachrichten.de

Tonix Pharmaceuticals Reports Financial Results and Highlights PDUFA Goal Date for TNX-102 SL in Fibromyalgia Treatment

August 11, 2025 | quiverquant.comQ

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

August 11, 2025 | globenewswire.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Pass Above 200-Day Moving Average - What's Next?

August 9, 2025 | marketbeat.com

Tonix Pharmaceuticals (TNXP) Expected to Announce Earnings on Friday

August 8, 2025 | marketbeat.com

What is Zacks Small Cap's Estimate for TNXP Q2 Earnings?

August 1, 2025 | marketbeat.com

TNXP: 2Q25 Financial Update and Deep Dive Into TNX-1500…

July 29, 2025 | finance.yahoo.com

Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened

July 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OKYO, ERAS, TNXP, and GOSS Company Descriptions

Erasca NASDAQ:ERAS

$1.64 +0.07 (+4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$1.64 0.00 (0.00%)

As of 04:10 PM Eastern

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Gossamer Bio NASDAQ:GOSS

$1.96 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.95 -0.01 (-0.51%)

As of 04:34 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

OKYO Pharma NASDAQ:OKYO

$2.65 +0.01 (+0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$2.64 -0.01 (-0.38%)

As of 04:15 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

Tonix Pharmaceuticals NASDAQ:TNXP

$51.43 -8.15 (-13.67%)

Closing price 01:03 PM Eastern

Extended Trading

$58.50 +7.07 (+13.75%)

As of 04:36 PM Eastern

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates. The company's priority is to submit a New Drug Application (NDA) to the FDA for TNX-102 SL (cyclobenzaprine HCl sublingual tablet), which has completed two positive Phase 3 studies for the management of fibromyalgia. TNX-102 SL is also being developed to treat fibromyalgia-type Long COVID, a chronic post-acute COVID-19 condition. Its TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted breakthrough therapy designation by the FDA. The company's rare disease development portfolio comprises TNX-2900, an intranasal potentiated oxytocin for the treatment of Prader-Willi syndrome (PWS). Its immunology portfolio includes TNX-1500, which is a biologic to address organ transplant rejection and autoimmune diseases. The company's infectious disease pipeline includes TNX-801, a vaccine in development to prevent smallpox and mpox. TNX-801 also serves as the live virus vaccine platform or recombinant pox vaccine platform for other infectious diseases, including TNX-1800 and TNX-1850, in development as a vaccine to protect against COVID-19. Its infectious disease development portfolio also comprises TNX-3900, and TNX-4200 are orally available CD45 antagonists in preclinical development. Tonix Pharmaceuticals Holding Corp. has collaboration agreement with Bilthoven Biologicals to advance TNX-801 mpox vaccine candidate; and with X-Chem, Inc. to develop broad-spectrum antivirals. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time